![]() |
![]() |
My Amedeo
![]() ![]() ![]() |
![]() |
|||||||||
Stroke prevention |
Chronic Heart Failure |
Free Subscription
1 Am Heart J |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Chronic Heart Failure is free of charge.
Randomized controlled trial of urinE chemiStry guided aCute heArt faiLure
treATmEnt (ESCALATE): Rationale and design.
Am Heart J. 2023 Aug 4:S0002-8703(23)00187-4. doi: 10.1016/j.ahj.2023.
PubMed
Abstract available
Heart Failure Hospitalizations Versus Cardiovascular Mortality in Heart Failure
Trials.
Am J Cardiol. 2023 Aug 7:S0002-9149(23)00596.
PubMed
Comparative Outcomes of Sacubitril/Valsartan Use After Hospitalization for Heart
Failure Among Medicare Beneficiaries Naive to Renin-Angiotensin System
Inhibitors.
Am J Cardiol. 2023;204:151-158.
PubMed
Abstract available
Electrical Synchrony Optimization for Left Bundle Branch Area Pacing in Patients
With Bradycardia and Heart Failure.
Am J Cardiol. 2023;203:436-443.
PubMed
Abstract available
Association of genetic risk and outcomes in patients with atrial fibrillation:
interactions with early rhythm control in the EAST-AFNET4 trial.
Cardiovasc Res. 2023 Jun 2:cvad027. doi: 10.1093.
PubMed
Abstract available
Cardiac reverse remodelling with vericiguat: Victory or no victory?
Eur J Heart Fail. 2023;25:1022-1024.
PubMed
Effect of dapagliflozin on health status and quality of life across the spectrum
of ejection fraction: Participant-level pooled analysis from the DAPA-HF and
DELIVER trials.
Eur J Heart Fail. 2023;25:981-988.
PubMed
Abstract available
Comparison of pulmonary congestion severity using artificial
intelligence-assisted scoring versus clinical experts: A secondary analysis of
BLUSHED-AHF.
Eur J Heart Fail. 2023;25:1166-1169.
PubMed
Abstract available
Effect of phosphodiesterase-5 inhibition on SystEmic Right VEntricular size and
function. A multicentre, double-blind, randomized, placebo-controlled trial:
SERVE.
Eur J Heart Fail. 2023;25:1105-1114.
PubMed
Abstract available
Exercise hypoxaemia in heart failure with preserved ejection fraction.
Eur J Heart Fail. 2023 Aug 2. doi: 10.1002/ejhf.2989.
PubMed
Moving towards a comprehensive heart failure management beyond ejection fraction.
Eur J Heart Fail. 2023 Aug 2. doi: 10.1002/ejhf.2987.
PubMed
Combining loop and thiazide diuretics for acute heart failure across the
estimated glomerular filtration rate spectrum: a post-hoc analysis of the
CLOROTIC trial.
Eur J Heart Fail. 2023 Aug 4. doi: 10.1002/ejhf.2988.
PubMed
Abstract available
Mineralocorticoid receptor antagonist use and the effects of empagliflozin on
clinical outcomes in patients admitted for acute heart failure: findings from
EMPULSE.
Eur J Heart Fail. 2023 Aug 4. doi: 10.1002/ejhf.2982.
PubMed
Abstract available
July 2023 at a glance: heart failure with preserved ejection fraction and
comorbidities.
Eur J Heart Fail. 2023;25:925-928.
PubMed
Phenotypic characterization of heart failure with preserved ejection fraction.
Eur J Heart Fail. 2023 Aug 10. doi: 10.1002/ejhf.2996.
PubMed
Artificial Intelligence and Heart Failure: A State-of-the-Art Review.
Eur J Heart Fail. 2023 Aug 10. doi: 10.1002/ejhf.2994.
PubMed
Abstract available
Incident Heart Failure Risk Reclassification with Race-Independent Estimated
Glomerular Filtration Rate: An NHLBI Pooled Cohorts Analysis.
J Card Fail. 2023 Aug 3:S1071-9164(23)00268.
PubMed
Abstract available
Vascular Disease Burden, Outcomes, and Benefit with Empagliflozin in Heart
Failure: Insights from the EMPEROR-Reduced Trial.
J Card Fail. 2023 Aug 7:S1071-9164(23)00275.
PubMed
Abstract available
Implementation of evidence-based heart failure management: Regional variations
between Japan and the USA.
J Cardiol. 2023 Aug 3:S0914-5087(23)00185-5. doi: 10.1016/j.jjcc.2023.
PubMed
Abstract available
Ythdf2 regulates cardiac remodeling through its mRNA target transcripts.
J Mol Cell Cardiol. 2023;181:57-66.
PubMed
Abstract available
Thank you for your interest in scientific medicine.
This policy is made possible thanks to
a media sponsorship by